ArticleUnited European gastroenterology journal2026
Higher Risk of Serious Infection in Offspring of Mothers With Biopsy-Proven MASLD: A Nationwide Cohort Study.
Article in United European gastroenterology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) has been linked to an increased risk of serious infection, but the impact of in utero exposure to maternal MASLD on the risk of infection in offspring remains unknown.
methodsThis nationwide cohort study included all singleton live born offspring exposed in utero to maternal biopsy-proven MASLD (1992-2017) in Sweden. Offspring born to mothers with MASLD (N = 239) were matched with up to five reference offspring (N = 1131) of mothers without MASLD by maternal age at delivery, calendar year of delivery, and parity. We used multivariable Cox regression to estimate adjusted hazard ratios (aHRs) for incident serious infection up until 2023. Results were also stratified by maternal histological severity of MASLD (simple steatosis vs. severe MASLD including steatohepatitis, any stage of liver fibrosis or cirrhosis).
resultsOver a median of 16.7 years of follow-up, 56 incident serious infections occurred in MASLD offspring (incidence rate [IR] 15.8/1000 person-years) and 140 incident serious infections occurred in reference offspring (IR 7.4/1000 person-years), which corresponded to an aHR of 1.81 (95% CI 1.23-2.68). The aHRs for incident serious infection were similar to offspring of mothers with simple steatosis and severe MASLD (1.97 vs. 1.70). This association was primarily explained by early-life infections (1-year aHR 3.11, 95% CI 1.74-5.58), with severe MASLD potentially being a major factor in the observed association during the first year. Results remained consistent across subgroups. DISCUSSION: Maternal MASLD, even simple steatosis, is associated with a higher hazard of serious offspring infection, highlighting the need for closer monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.